Loading
GlyTR Therapeutics is developing immune treatments that recognise sugar molecules found in large amounts on many kinds of cancer cell, rather than a single protein. Its medicines are still in laboratory and animal testing.
GlyTR Therapeutics licenses Glycan-dependent T cell Recruiter (GlyTR) technology from the University of California, Irvine, where its founders Michael Demetriou and Raymond Zhou developed it. GlyTR molecules use high-avidity lectin binding to tumour-associated carbohydrate antigens and are made both as bispecific proteins that recruit T cells (GlyTR1 and GlyTR2) and as CAR-T cells; the foundational study was published in Cell in 2025, and the company says it is advancing toward clinical trials. In fiscal year 2026 NCI awarded it USD 1,002,331 under STTR award 4R42CA302415-02 to increase target density for GlyTR immunotherapy.
Investors not recorded; see the round sources.
| Round | Year | Amount | Source |
|---|---|---|---|
| Grant · NCI STTR award (R42) 4R42CA302415-02: Maximizing GlyTR pan-cancer immunotherapy by enhancing target density | 2026 | $1M | reporter.nih.gov |
Amounts only where the cited source states them. Rounds without a public source are not listed.
GlyTR1 is an experimental protein from GlyTR Therapeutics that latches onto sugar molecules crowded on cancer cells and pulls immune T cells in to attack. It has been tested only in the laboratory and in animals.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/